Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Arch Toxicol. 2009 Jun 21;83(10):909–924. doi: 10.1007/s00204-009-0450-y

Figure 2.

Figure 2

Projections of Principal Component 1 versus Principal Component 2 from the Principal Component Analysis (PCA) of the data from the metabolomic study reveal two groupings: One grouping with ciprofibrate-treated animals and a second grouping of N-EtFOSE-treated and control animal. Serum was mixed in a 1:1 ratio (v/v) with phosphate buffer (pH = 7.4) containing TSP as internal standard and CPMG spectra were recorded on a 600-NMR instrument as described under Materials and Methods. The spectra were integrated manually and adjusted for TSP prior to PCA. Each word-label in the Figure denotes one animal.